No definition available.
Disorders of myoneural junction and muscle in diseases classified elsewhere
DOID EFO Endpoint Browser PheWeb
G6_MYOMUSCINOTH
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
270 |
4. Check minimum number of eventsNone |
270 |
5. Include endpointsNone |
270 |
6. Filter based on genotype QC (FinnGen only) |
270 |
Control definitions (FinnGen only)
- Control exclude
- G6_MYONEU
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Disorders of myoneural junction and muscle in diseases classified elsewhere
based on the number of shared cases.
Similar with more cases:
- Diseases of the myoneural junction and muscle
- Autoimmune diseases
- Used for control exclusion in common control thyroid runs
- Neurological diseases
- Neurological diseases, wide definition
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1357 | 973 | 377 |
| Only index persons | 1184 | 865 | 319 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.03 | 0.01 |
| Only index persons | 0.03 | 0.03 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 61.99 | 62.44 | 60.81 |
| Only index persons | 61.00 | 61.15 | 60.58 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 270 | 204 | 66 |
| Unadjusted period prevalence (%) | 0.06 | 0.07 | 0.03 |
| Median age at first event (years) | 57.26 | 56.19 | 60.59 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 247
- Matched controls
- 2468
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G73.7*M35.0
ICD-10 Finland
Myopathy in sicca syndrome [Sjögren]
+∞
99.9
89
*
M35.0
ICD-10 Finland
Sicca syndrome [Sjögren]
96.2
92.7
99
17
P01BA02
ATC
hydroxychloroquine; oral
19.6
71.6
118
110
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
13.8
60.2
117
151
G73.7
ICD-10 Finland
Myopathy in other diseases classified elsewhere
+∞
46.3
43
*
M32.9
ICD-10 Finland
Systemic lupus erythematosus, unspecified
115.6
44.6
47
5
L04AX01
ATC
azathioprine; systemic
18.9
39.5
62
43
NK6QA
NOMESCO Finland
Measurement of bone density from tow or more locations with X-ray
10.7
31.7
65
80
G73.7*M32.1
ICD-10 Finland
Myopathy in systemic lupus erythematosus
+∞
30.9
29
*
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
9.2
27.5
61
85
M32.1
ICD-10 Finland
Systemic lupus erythematosus with organ or system involvement
84.7
27.4
30
*
L04AX03
ATC
methotrexate; systemic (immunosuppressants)
7.1
24.8
66
121
M05BA04
ATC
alendronic acid; oral
7.6
24.7
62
104
M35.9
ICD-10 Finland
Systemic involvement of connective tissue, unspecified
62.8
24.6
28
5
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
4.2
24.5
140
590
H02AB07
ATC
prednisone; oral
5.3
24.2
86
226
H02AB06
ATC
prednisolone; systemic
4.0
23.0
170
881
G73.0*E05.9
ICD-10 Finland
Myasthenic syndromes in thyrotoxicosis [hyperthyroidism]
+∞
22.2
21
*
M32.8
ICD-10 Finland
Other forms of systemic lupus erythematosus
114.3
19.9
21
*
M32.0
ICD-10 Finland
Drug-induced systemic lupus erythematosus
216.6
19.9
20
*
L04AA06
ATC
mycophenolic acid; systemic
25.1
19.5
27
12
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.5
19.5
151
766
G73.1*C80.99
ICD-10 Finland
Eaton-Lambert syndrome
+∞
19.0
18
*
G73.0*E11.4
ICD-10 Finland
Non-insulin-dependent diabetes mellitus - Diabetic amyotrophy
+∞
17.9
17
*
N07AA02
ATC
pyridostigmine; systemic
+∞
17.9
17
*
H02AB04
ATC
methylprednisolone; systemic
4.3
16.7
70
209
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
6.4
16.5
45
83
G72.9
ICD-10 Finland
Myopathy, unspecified
+∞
14.7
14
*
G73.0*E10.4
ICD-10 Finland
Insulin-dependent diabetes mellitus - Diabetic amyotrophy
+∞
14.7
14
*
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
4.9
14.5
50
121
G73.7*M34.8
ICD-10 Finland
Myopathy in scleroderma
+∞
13.7
13
*
7100A
ICD-9 Finland
Diffuse diseases of connective tissue, Systemic lupus erythematosus
147.8
13.6
14
*
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
2.8
13.3
142
810
M79.0
ICD-10 Finland
Rheumatism, unspecified
7.6
13.2
31
46
NG1AA
NOMESCO Finland
Knee X-ray examination without contrast
4.0
12.6
54
161
L01BA01
ATC
methotrexate; systemic (folic acid analog.)
8.5
12.5
27
35
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.8
12.4
102
491
H04.10
ICD-10 Finland
Dry eye syndrome
4.0
12.3
52
153
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
6.7
12.1
31
52
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
4.2
11.7
47
132
G73.7*M05.3
ICD-10 Finland
Rheumatoid myopathy
125.6
11.5
12
*
73410
ICD-8 Finland
Diffuse diseases of connective tissue, Systemic lupus erythematosus
125.6
11.5
12
*
G05.8*M32.1
ICD-10 Finland
Encephalitis in systemic lupus erythematosus
125.6
11.5
12
*
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
4.2
11.2
44
121
C03CA01
ATC
furosemide; systemic
2.8
11.2
89
414
ND2DA
NOMESCO Finland
Bilateral hand X-ray examination
9.5
11.0
22
25
M32
ICD-10 Finland
Systemic lupus erythematosus
114.7
10.5
11
*
G70.0
ICD-10 Finland
Myasthenia gravis
+∞
10.5
10
*
L88
ICPC
Rheumatoid/seropositive arthritis
7.3
10.2
24
36
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
10.2
10.0
19
20
M35.1
ICD-10 Finland
Other overlap syndromes
27.3
9.9
13
5
H19.3*M35.0
ICD-10 Finland
Keratoconjunctivitis sicca
57.3
9.7
11
*
M05.8
ICD-10 Finland
Other seropositive rheumatoid arthritis
5.0
9.7
31
69
M34.9
ICD-10 Finland
Systemic sclerosis, unspecified
31.4
9.5
12
*
N08.5*M32.1
ICD-10 Finland
Glomerular disorders in systemic lupus erythematosus
103.8
9.5
10
*
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.8
9.4
71
315
108
Kela drug reimbursment
Myasthenia gravis
+∞
9.4
9
*
N06AA09
ATC
amitriptyline; systemic
3.4
9.0
45
151
M06.9
ICD-10 Finland
Rheumatoid arthritis, unspecified
8.1
8.8
19
25
XPX99
NOMESCO Finland
Other diagnostic examination of periferal vessel
4.5
8.8
31
77
N03AX16
ATC
pregabalin; oral
2.5
8.6
81
403
E05.9
ICD-10 Finland
Thyrotoxicosis, unspecified
5.9
8.5
23
42
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
3.7
8.5
37
111
M33.2
ICD-10 Finland
Polymyositis
93.1
8.5
9
*
NXL00
NOMESCO Finland
Biopsy of muscle
93.1
8.5
9
*
C08CA05
ATC
nifedipine; systemic
4.3
8.4
31
80
NH3DA
NOMESCO Finland
Bilateral foot X-ray examination
7.5
8.4
19
27
S01KA02
ATC
hypromellose; ophthalmic
10.0
8.4
16
17
G73.1
ICD-10 Finland
Lambert-Eaton syndrome
+∞
8.4
8
*
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.0
8.3
50
192
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
3.6
8.2
38
120
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
4.6
8.2
28
67
R06.0
ICD-10 Finland
Dyspnoea
2.4
8.2
79
398
Z01.8
ICD-10 Finland
Other specified special examinations
2.5
8.2
71
339
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
3.7
8.1
35
105
E10.7
ICD-10 Finland
Type 1 diabetes mellitus, With multiple complications
8.2
8.0
17
22
N03AX12
ATC
gabapentin; oral
2.8
8.0
55
228
L04AA01
ATC
[U] ciclosporin; systemic
9.9
7.9
15
16
SBA10
NOMESCO Finland
Measurement of excretion of saliva
15.7
7.8
12
8
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
3.5
7.8
36
114
ELA30
NOMESCO Finland
Biopsy of salivary gland
46.5
7.8
9
*
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
3.4
7.7
38
127
A10AB01
ATC
insulin (human); parenteral (insulins and analog. for injection, fast-acting)
6.8
7.6
18
28
A10AC01
ATC
insulin (human); parenteral (insulins and analog. for injection, intermediate-acting)
4.1
7.5
28
74
N06AX21
ATC
duloxetine; oral
3.0
7.3
42
156
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
4.9
7.3
23
51
R50.9
ICD-10 Finland
Fever, unspecified
2.9
7.2
46
183
H26.3
ICD-10 Finland
Drug-induced cataract
31.0
7.2
9
*
I15.1
ICD-10 Finland
Hypertension secondary to other renal disorders
12.5
7.2
12
10
NA2AA
NOMESCO Finland
Thoracal spine X-ray examination without contrast
7.4
7.1
16
23
A02BC02
ATC
pantoprazole; systemic
2.1
7.0
174
1308
J01FF01
ATC
clindamycin; systemic
2.3
7.0
78
419
E0000UV
ATC
NA
2.1
7.0
110
686
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
2.9
6.9
43
168
L93.0
ICD-10 Finland
Discoid lupus erythematosus
41.2
6.8
8
*
L28
ICPC
Limited function/disability (L)
2.6
6.8
51
223
F34.1
ICD-10 Finland
Dysthymia
6.8
6.8
16
25
K11.2
ICD-10 Finland
Sialoadenitis
5.8
6.8
18
33
WZC10
NOMESCO Finland
Extensive specialist consultion with written report
4.6
6.7
22
51
TPH04
NOMESCO Finland
Cathetrisation of vein
2.4
6.6
64
319
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
7.2
6.6
15
22
A10AA01
ATC
NA
7.2
6.6
15
22
M79.7
ICD-10 Finland
Fibromyalgia
5.0
6.6
20
43
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.1
6.6
36
127
E05.0
ICD-10 Finland
Thyrotoxicosis with diffuse goitre
4.7
6.5
21
48
M34.8
ICD-10 Finland
Other forms of systemic sclerosis
71.6
6.5
7
*
N08.39*E10.2
ICD-10 Finland
Insulin-dependent diabetes mellitus - Diabetic nephropathy
14.8
6.4
10
7
S97
ICPC
Chronic ulcer skin
4.7
6.3
20
45
J02AC01
ATC
fluconazole; systemic
2.0
6.3
121
805
NH1AA
NOMESCO Finland
Ankle X-ray examination without contrast
3.9
6.3
25
70
P01BA01
ATC
chloroquine; systemic
18.6
6.3
9
5
E10.2
ICD-10 Finland
Type 1 diabetes mellitus, With renal complications
18.6
6.3
9
5
SBB10
NOMESCO Finland
Teeth copy
4.0
6.3
24
65
NJ3BG
NOMESCO Finland
MRI examination of extremities with high intensity magnet
+∞
6.3
6
*
N16.4*M32.1
ICD-10 Finland
Renal tubulo-interstitial disorders in systemic lupus erythematosus
+∞
6.3
6
*
R03CA02
ATC
ephedrine; oral
+∞
6.3
6
*
G73.0
ICD-10 Finland
Myasthenic syndromes in endocrine diseases
+∞
6.3
6
*
SPAT1215
SPAT
Assessment of need for medical rehabilitation
4.9
6.3
19
41
J01MA12
ATC
levofloxacin; systemic
2.4
6.2
55
261
H03AA01
ATC
levothyroxine sodium; systemic
2.1
6.2
79
446
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
3.3
6.1
30
100
UJF30
NOMESCO Finland
Ileoscopy through colon
3.1
6.1
34
122
M01AX17
ATC
nimesulide; oral
2.2
6.1
72
391
M01AH02
ATC
rofecoxib; oral
2.7
6.1
44
186
L30.9
ICD-10 Finland
Dermatitis, unspecified
2.4
6.0
54
259
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
72
75
12.73
64.89
5.3
1.9
—
—
—
0
0
68
67
13.23
63.52
1.6
1.3
6.7
1.8
u/ml
—
28
10
68
68
13.03
62.88
1.7
1.3
2.4
2.1
u/ml
0.30
31
12
59
55
13.45
56.84
1.6
1.3
21.3
13.7
u/ml
—
12
6
53
56
11.53
46.65
1.5
1.3
—
—
—
0
0
42
54
9.03
31.55
1.6
1.3
63.7
35.9
u/ml
—
11
9
28
22
14.08
29.32
1.4
1.2
2.6
—
u/ml
—
5
0
28
23
13.47
28.55
1.4
1.2
59.1
94.4
u/ml
—
7
5
197
1086
4.01
24.11
13.2
5.6
26.0
28.3
%
2.49
191
1002
194
1077
3.85
23.07
12.5
5.3
59.5
57.1
%
2.13
188
1001
17
11
16.43
19.51
1.1
1.1
—
—
—
0
0
49
121
4.73
18.96
7.3
3.3
1.5
1.9
mmol/l
0.21
40
93
135
664
3.07
18.27
4.4
1.9
323.5
148.3
u/l
0.51
130
630
209
1327
3.54
17.85
16.1
9.3
4.0
4.0
e9/l
0.15
193
1163
55
157
4.14
17.61
11.0
6.6
10.7
9.4
mmol/l
0.71
50
146
55
166
3.91
16.23
1.9
3.0
64.0
67.3
g/l
1.95
47
152
111
530
2.86
15.27
3.1
2.1
3.5
3.2
mg/l
0.73
97
454
166
985
2.78
14.81
3.3
2.3
81.7
78.3
nmol/l
0.72
153
869
169
1031
2.71
13.96
10.0
5.3
1.2
1.2
mmol/l
0.28
159
924
67
256
3.15
13.57
11.9
5.0
1.1
1.0
mmol/l
0.09
61
230
22
35
6.75
13.50
3.5
3.4
56.3
61.4
%
0.70
22
35
22
35
6.75
13.50
3.4
2.9
3.6
5.2
e9/l
1.42
22
35
79
335
2.92
13.30
3.2
2.9
0.8
0.8
mmol/l
0.56
70
316
78
334
2.88
12.85
2.3
1.8
—
—
—
0
0
175
1122
2.59
12.49
12.1
6.2
1.2
1.2
mmol/l
0.32
148
949
135
778
2.47
11.98
6.5
3.1
—
—
—
0
0
34
90
4.18
11.88
2.3
2.3
1.8
1.7
g/l
0.24
27
77
58
221
3.07
11.69
2.9
4.6
260.0
240.5
u/l
0.75
52
209
136
796
2.43
11.54
3.6
3.3
2.3
2.4
mmol/l
0.67
118
697
31
80
4.25
11.19
2.4
1.5
—
—
—
0
0
15
19
8.30
11.12
1.3
1.0
—
—
—
0
0
21
40
5.61
10.77
1.6
1.4
—
—
—
0
0
35
102
3.79
10.71
1.8
2.2
44.0
40.3
u/l
0.39
30
90
25
57
4.73
10.50
1.2
1.9
—
—
—
0
0
31
87
3.90
9.98
2.7
1.7
—
—
—
0
0
223
1693
2.82
9.94
11.6
4.1
17.2
12.1
mm/h
5.11
215
1546
72
336
2.56
9.75
3.8
2.3
10.5
13.7
umol/l
3.45
66
308
229
1774
2.92
9.59
14.9
7.1
75.5
78.3
u/l
0.54
224
1646
21
45
4.98
9.47
2.2
1.7
124.6
129.7
g/l
0.33
13
30
18
34
5.60
9.29
1.3
1.1
2.9
1.2
u/ml
—
9
9
19
38
5.30
9.24
1.3
1.1
3.7
4.4
u/ml
0.14
11
16
149
969
2.20
9.18
7.5
4.0
34.1
35.8
g/l
2.83
135
905
107
613
2.23
9.01
5.4
2.9
0.3
0.5
e6/l
0.82
86
448
14
21
6.98
8.98
1.3
1.2
—
—
—
0
0
14
21
6.98
8.98
1.3
1.2
—
—
—
0
0
25
65
4.14
8.91
3.5
2.6
—
—
—
0
0
37
128
3.19
8.68
3.3
3.6
3.9
4.5
pmol/l
2.28
32
108
14
22
6.66
8.61
1.3
1.2
—
—
—
0
0
14
22
6.66
8.61
1.3
1.2
—
—
—
0
0
14
22
6.66
8.61
1.3
1.2
—
—
—
0
0
149
987
2.14
8.54
3.9
2.7
152.6
99.4
ug/l
1.76
134
906
12
6
20.83
8.54
1.1
1.0
—
—
—
0
0
140
909
2.12
8.42
2.3
2.0
101.6
96.6
pmol/l
0.57
78
454
62
289
2.49
8.31
4.3
2.3
20.1
23.1
%
0.97
54
245
14
23
6.37
8.26
1.7
1.2
—
—
—
0
0
159
1091
2.11
8.18
5.8
3.7
0.0
0.0
estimate
0.00
35
207
64
305
2.44
8.17
4.1
2.2
2.1
2.4
g/l
2.56
58
280
108
643
2.13
8.08
5.0
3.1
2743.4
1148.3
ng/l
1.23
91
535
16
31
5.42
8.03
1.3
1.2
—
—
—
0
0
18
39
4.87
8.00
9.4
5.2
1900.0
139.8
iu/ml
—
5
5
17
37
4.84
7.51
1.4
1.6
—
—
—
0
0
159
1113
2.04
7.49
6.0
3.7
0.0
0.0
estimate
0.00
31
197
129
842
2.02
7.36
6.1
3.6
44.5
37.3
ng/l
0.23
96
573
23
65
3.77
7.32
1.9
4.5
45.6
165.2
mg/l
0.66
17
53
23
65
3.77
7.32
1.9
4.6
32.4
28.1
mg/l
0.36
16
53
156
1102
1.98
6.97
7.6
4.9
0.0
0.0
estimate
0.00
34
207
20
53
4.00
6.94
1.6
1.5
—
—
—
0
0
26
83
3.36
6.92
1.8
2.2
3.2
3.2
g/l
0.07
16
68
19
49
4.10
6.83
1.4
1.6
—
—
—
0
0
14
28
5.22
6.78
1.4
1.6
—
—
—
0
0
24
74
3.46
6.73
1.7
1.4
313.1
324.9
ug/g
0.12
16
40
12
21
5.93
6.64
2.0
1.9
—
—
—
0
0
16
37
4.53
6.58
1.3
1.6
—
—
—
0
0
16
37
4.53
6.58
1.4
1.2
—
—
—
0
0
42
181
2.56
6.56
6.5
3.4
113.4
82.3
ng/l
0.98
33
158
89
530
2.01
6.39
1.5
1.3
3.5
1.6
u/ml
0.26
17
145
10
15
6.88
6.35
1.4
1.0
—
—
—
0
0
15
34
4.61
6.32
1.1
1.3
—
—
—
0
0
75
421
2.08
6.32
2.3
1.7
1261.5
1143.5
nmol/l
0.56
61
312
13
26
5.20
6.29
1.4
1.7
—
—
—
0
0
26
90
3.09
6.08
1.8
2.2
3.6
3.9
g/l
0.43
16
68
26
90
3.09
6.08
1.8
2.2
7.1
7.6
g/l
0.58
17
70
26
90
3.09
6.08
1.8
2.2
—
—
—
0
0
12
24
5.19
5.80
2.0
1.8
—
—
—
0
0
17
46
3.88
5.74
2.6
1.5
2580.5
22331.0
e6/l
0.83
11
30
19
56
3.57
5.70
1.9
1.5
—
—
—
0
0
38
167
2.48
5.69
1.8
1.4
—
—
—
0
0
90
560
1.91
5.57
3.6
2.8
353.8
5894.5
umol/l
2.22
76
481
23
78
3.13
5.56
2.0
2.6
0.2
0.9
g/l
1.37
17
70
32
131
2.64
5.53
1.3
1.2
309.3
350.6
u/ml
0.06
26
118
86
531
1.91
5.43
2.9
2.0
—
—
—
0
0
29
114
2.73
5.42
1.6
1.3
—
—
—
0
0
108
718
1.84
5.41
3.2
2.3
55.0
56.7
u/l
0.23
96
659
72
420
1.97
5.37
1.3
1.3
49.3
30.5
iu/ml
0.86
31
141
13
30
4.50
5.35
1.4
1.6
—
—
—
0
0
57
306
2.09
5.33
4.2
4.3
32.6
32.6
%
0.01
42
194
85
537
1.85
4.94
1.5
1.5
21.7
22.1
nmol/l
0.08
73
444
23
85
2.86
4.82
1.9
2.2
11.0
10.5
g/l
0.13
16
75
159
1216
1.75
4.74
6.7
5.7
9.0
10.6
umol/l
2.43
148
1152
21
75
2.95
4.67
2.0
2.3
36.0
37.7
g/l
0.45
15
66
80
505
1.83
4.62
2.2
1.6
1.2
1.0
mg/l
0.39
63
402
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
17
54
3.29
4.57
3.5
2.3
0.2
0.4
u/ml
—
9
26
166
1294
1.73
4.54
7.2
4.3
6.5
6.6
mmol/l
0.18
157
1204
28
119
2.51
4.50
1.8
1.7
—
—
—
0
0
18
60
3.14
4.49
1.1
1.1
—
10.8
—
0
8
141
1054
1.71
4.47
4.0
3.6
—
—
—
0
0
91
604
1.76
4.42
6.5
4.0
0.0
0.0
estimate
0.00
32
208
43
224
2.09
4.32
1.6
1.8
—
—
—
0
0
17
56
3.17
4.32
2.3
1.6
10.3
5.7
iu/l
—
6
18
8
9
9.12
4.31
1.9
2.0
—
—
—
0
0
8
9
9.12
4.31
1.9
2.0
—
—
—
0
0
8
9
9.12
4.31
1.9
2.0
—
—
—
0
0
71
442
1.82
4.25
2.9
2.7
2.5
2.5
mmol/l
0.01
62
391
210
1776
1.82
4.06
5.9
4.1
15.2
14.8
pmol/l
1.65
190
1599
16
55
3.03
3.80
2.9
1.3
—
—
—
0
0
7
8
8.94
3.79
1.4
1.5
—
—
—
0
0
72
465
1.75
3.77
1.6
1.8
471.5
470.9
pmol/l
0.01
58
384
59
361
1.81
3.70
4.0
2.6
0.6
1.0
e6/l
1.54
37
194
42
230
1.98
3.69
1.9
1.9
—
—
—
0
0
101
721
1.64
3.63
3.3
2.9
30.6
28.9
u/l
0.39
93
687
7
9
7.95
3.58
1.4
1.4
—
—
—
0
0
38
203
2.01
3.57
5.1
3.3
—
—
—
0
0
17
63
2.81
3.56
1.4
1.1
—
—
—
0
0
11
31
3.66
3.52
1.2
1.4
—
—
—
0
0
7
10
7.15
3.38
1.4
1.6
—
—
—
0
0
63
404
1.73
3.36
1.3
1.3
17.5
10.9
u/ml
0.17
15
150
8
15
5.46
3.21
2.3
1.7
—
—
—
0
0
8
15
5.46
3.21
2.3
1.7
—
—
—
0
0
8
15
5.46
3.21
2.3
1.7
—
—
—
0
0
8
15
5.46
3.21
2.3
1.7
—
—
—
0
0
47
280
1.82
3.20
7.5
6.7
—
—
—
0
0
33
176
2.00
3.12
7.3
3.6
1.2
1.2
mmol/l
0.37
28
158
16
62
2.68
3.10
1.6
2.1
10.8
12.0
mg/l
0.26
16
56
8
16
5.12
3.07
1.1
1.3
—
—
—
0
0
5
5
10.15
2.99
1.8
1.4
—
—
—
0
0
41
240
1.84
2.96
7.1
6.5
0.9
1.3
mmol/l
0.16
32
195
8
17
4.81
2.94
1.1
1.1
—
—
—
0
0
34
188
1.92
2.91
2.1
2.4
3.7
6.2
ug/l
0.77
24
166
9
22
4.19
2.91
1.1
1.3
—
—
—
0
0
9
22
4.19
2.91
2.1
1.8
—
—
—
0
0
9
22
4.19
2.91
2.1
1.8
—
—
—
0
0
9
22
4.19
2.91
2.1
1.8
—
—
—
0
0
177
1495
1.53
2.79
4.6
2.9
52.4
46.0
u/l
0.44
163
1398
5
6
8.46
2.76
1.0
1.2
106.4
103.2
%
—
5
6
5
6
8.46
2.76
1.0
1.2
—
—
—
0
0
5
6
8.46
2.76
1.0
1.0
1752.0
1828.2
miu/ml
—
5
6
7
14
5.10
2.74
1.4
1.0
—
—
—
0
0
6
10
6.11
2.71
3.2
2.2
—
—
—
0
0
5
7
7.25
2.56
1.2
1.1
—
—
—
0
0
51
333
1.66
2.52
4.1
2.8
3.9
2.9
e6/l
0.32
30
168
6
13
4.69
2.28
1.2
1.3
—
—
—
0
0
7
18
3.96
2.26
1.9
2.1
—
—
—
0
0
244
2262
1.82
2.23
34.3
13.1
23.4
22.1
mg/l
0.22
222
1764
8
24
3.40
2.19
1.4
1.0
—
—
—
0
0
8
25
3.27
2.11
1.4
1.0
—
—
—
0
0
42
278
1.60
1.97
39.6
19.9
1.4
1.3
inr
—
6
43
30
184
1.71
1.88
8.4
3.9
5.6
5.9
kpa
1.05
30
179
10
40
2.56
1.85
1.8
1.5
—
—
—
0
0
6
17
3.58
1.84
1.0
1.1
—
—
—
0
0
6
17
3.58
1.84
6.7
1.6
14.7
17.2
ug/l
—
6
17
104
839
1.39
1.83
6.5
3.8
—
—
—
0
0
5
12
4.22
1.83
1.4
2.3
1328.8
676.2
u/ml
—
5
12
59
429
1.48
1.83
5.1
3.4
929.3
185.8
ng/l
0.40
47
328
230
2126
1.55
1.80
7.2
4.9
1.8
2.5
mu/l
0.59
212
1930
7
24
2.97
1.73
1.1
1.2
—
—
—
0
0
10
212
0.45
1.73
1.7
1.7
—
—
—
0
0
5
13
3.90
1.72
1.0
1.1
—
—
—
0
0
5
14
3.62
1.62
1.8
1.1
—
—
—
0
0
5
15
3.38
1.53
2.0
1.2
2.6
1.9
mmol/l
—
5
15
6
21
2.90
1.51
1.7
1.2
—
—
—
0
0
6
21
2.90
1.51
1.0
1.0
—
—
—
0
0
9
37
2.48
1.49
1.3
1.3
—
—
—
0
0
9
37
2.48
1.49
1.3
1.3
—
—
—
0
0
9
37
2.48
1.49
1.3
1.3
—
—
—
0
0
9
37
2.48
1.49
1.1
1.1
—
—
—
0
0
9
37
2.48
1.49
1.3
1.3
—
—
—
0
0
9
37
2.48
1.49
1.3
1.3
—
—
—
0
0
9
37
2.48
1.49
1.3
1.3
—
—
—
0
0
10
45
2.27
1.48
1.4
1.7
—
—
—
0
0
35
239
1.53
1.46
1.5
1.8
1.5
1.5
%
0.15
28
212
7
28
2.54
1.46
1.1
1.2
—
—
—
0
0
53
396
1.42
1.43
1.7
1.5
—
—
—
0
0
14
75
1.91
1.37
2.1
1.7
—
—
—
0
0
20
121
1.71
1.35
6.7
8.2
95.0
94.3
%
0.37
20
121
153
1352
1.30
1.34
3.1
3.0
—
—
—
0
0
10
48
2.13
1.29
1.3
1.3
—
—
—
0
0
11
55
2.04
1.29
1.5
1.2
—
—
—
0
0
9
44
2.08
1.28
1.6
1.5
—
—
—
0
0
9
44
2.08
1.28
1.6
1.5
—
—
—
0
0
36
258
1.46
1.22
7.4
6.1
104.0
103.8
mmol/l
0.09
36
251
26
174
1.55
1.21
2.3
2.9
39.2
46.9
u/ml
0.12
26
168
11
57
1.97
1.18
1.2
1.3
—
—
—
0
0
61
486
1.33
1.12
7.2
4.1
1.0
1.0
kg/l
0.05
15
61
23
155
1.53
1.05
5.1
2.7
4.5
4.4
kpa
0.13
23
150
5
22
2.30
1.04
1.2
2.0
—
—
—
0
0
7
34
2.09
1.03
1.1
1.1
—
2.6
—
0
13
6
27
2.25
0.94
1.7
1.2
—
—
—
0
0
6
27
2.25
0.94
1.0
1.3
—
—
—
0
0
9
52
1.76
0.93
1.2
1.3
—
—
—
0
0
24
169
1.46
0.91
2.6
2.5
54.2
67.7
ml/min/173m2
1.12
14
68
30
225
1.38
0.82
3.8
2.2
33.0
29.2
u/l
0.62
25
195
6
32
1.89
0.82
1.5
1.3
—
—
nmol/l
—
0
0
32
243
1.36
0.82
2.1
2.2
3.9
7.8
umol/l
3.23
26
210
10
59
1.72
0.77
1.4
1.3
—
—
—
0
0
9
56
1.63
0.73
1.1
1.1
—
—
—
0
0
53
442
1.25
0.70
1.6
1.4
—
—
—
0
0
224
2150
1.25
0.66
26.1
12.6
75.1
80.0
ml/min/173m2
2.15
203
1747
23
173
1.36
0.64
1.2
1.2
229.6
180.4
iu/ml
—
7
74
13
88
1.50
0.62
1.2
1.2
—
—
—
0
0
18
131
1.40
0.61
1.5
1.3
—
—
—
0
0
0
22
0.00
0.59
0.0
2.5
—
13.6
—
0
22
213
2045
1.20
0.55
29.2
14.1
36.7
39.8
%
2.98
135
1508
6
98
0.60
0.53
2.0
1.7
—
—
—
0
0
228
2213
1.19
0.45
5.5
4.6
6.0
5.9
mmol/l
0.25
207
2024
0
16
0.00
0.41
0.0
3.7
—
—
—
0
0
12
88
1.38
0.40
1.3
1.2
—
—
—
0
0
22
185
1.21
0.30
1.8
1.7
—
—
—
0
0
24
204
1.19
0.30
1.8
1.9
—
—
—
0
0
8
64
1.26
0.27
1.8
1.4
—
245.6
—
0
29
5
73
0.68
0.26
1.8
1.6
—
—
—
0
0
0
10
0.00
0.21
0.0
2.7
—
—
—
0
0
0
10
0.00
0.21
0.0
2.7
—
—
—
0
0
216
2122
1.09
0.19
7.6
5.7
40.3
39.7
mmol/mol
0.42
197
1970
29
316
0.91
0.15
3.9
4.7
26.0
21.6
%
0.64
14
155
22
243
0.90
0.14
3.7
3.0
0.8
0.7
ug/l
0.17
17
150
28
257
1.10
0.14
2.6
4.2
3.2
24.2
ug/l
0.70
22
215
8
100
0.79
0.14
5.9
2.3
1.1
1.1
%
—
8
100
218
2156
1.06
0.10
4.7
3.9
1.4
1.3
mmol/l
1.54
194
1969
10
87
1.16
0.09
1.3
1.4
—
—
—
0
0
226
2240
1.05
0.08
5.1
4.4
1.5
1.5
mmol/l
1.43
205
2061
5
65
0.76
0.08
1.6
1.4
—
—
—
0
0
232
2302
1.06
0.08
5.6
5.0
2.7
2.8
mmol/l
1.32
210
2114
227
2258
1.03
0.04
5.1
4.4
4.6
4.8
mmol/l
1.40
206
2086
11
118
0.93
0.03
1.2
1.0
—
—
—
0
0
66
661
1.00
0.00
1.6
1.6
1.8
1.4
mmol/l
0.62
55
560
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
20.1
—
0
7
7
76
0.92
0.00
1.4
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint G6_MYOMUSCINOTH and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_MYOMUSCINOTH | 2.496 [2.04, 3.06] | < 0.001 |
| Birth year | 1.002 [0.99, 1.01] | 0.715 |
During the follow-up period (1.1.1998 — 31.12.2019), 313 out of 874 females with G6_MYOMUSCINOTH died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_MYOMUSCINOTH | 2.303 [1.64, 3.22] | < 0.001 |
| Birth year | 0.984 [0.97, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 124 out of 312 males with G6_MYOMUSCINOTH died.
Mortality risk
Mortality risk for people of age
years, who have G6_MYOMUSCINOTH.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.284% | 0.376% |
| 5 | 1.534% | 2.586% |
| 10 | 3.878% | 6.089% |
| 15 | 7.889% | 11.542% |
| 20 | 14.235% | 18.932% |
Relationships between endpoints
↥Index endpoint: G6_MYOMUSCINOTH – Disorders of myoneural junction and muscle in diseases classified elsewhere
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data